Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Clinical trial NCT07061626 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07061626
- Sponsor
- Plus Therapeutics
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2027-03-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.